Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124982 · ClinicalTrials.gov registry record · Phase 3
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
A Phase 3 study of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,286
- Enrollment target
- 20
- Study locations
NCT00124982 is a Phase 3 study of Rheumatoid Arthritis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,286 participants, below the 4,684-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00124982, a Phase 3 study of Rheumatoid Arthritis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,286 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for rheumatoid arthritis (RA) in subjects with active RA. Secondary objectives assessed the clinical efficacy of combination treatment, including disease activity, physical function, and quality of life outcomes.
Conditions Studied
Interventions
- DRUG Abatacept
- DRUG Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
- DRUG Anti-Tumor Necrosing Factor (TNF) Therapy
Study Locations (20)
California
- Local Institution - Long Beach
- Local Institution - Palm Springs
- Local Institution - Palo Alto
- Local Institution - San Diego
- Local Institution - Santa Monica
Florida
- Local Institution - Aventura
- Local Institution - Clearwater
- Local Institution - Fort Lauderdale
- Local Institution - Jupiter
Arizona
- Local Institution - Paradise Valley
- Local Institution - Peoria
- Local Institution - Tucson
Connecticut
- Local Institution - Danbury
- Local Institution - Hamden
- Local Institution - Trumbull
Alabama
- Local Institution - Birmingham
- Local Institution - Huntsville
Colorado
- Local Institution - Colorado Springs
- Local Institution - Denver
District of Columbia
- Local Institution - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,286 participants |
| Start Date | 2005-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00124982
The ClinicalTrials.gov registry entry for NCT00124982 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,286 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,684-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (73% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Abatacept is the first listed.
NCT00124982 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00124982 about?
NCT00124982 is a clinical study titled "Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy". The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for rheumatoid arthritis (RA) in subjects with active RA. Secondary object...
What is the current status of trial NCT00124982?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,286 participants. The study started on 2005-04. Estimated completion is 2009-08.
What conditions does trial NCT00124982 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00124982?
The interventions under investigation include: Abatacept (DRUG), Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (DRUG), Anti-Tumor Necrosing Factor (TNF) Therapy (DRUG).
Who is sponsoring clinical trial NCT00124982?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00124982 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.